LEADS BIOLABS-B (09887) announced that the price stabilization period in relation to its global offering concluded on August 21, 2025 (Thursday), being the 30th day after the deadline for submitting applications under the Hong Kong public offering. The price stabilization actions undertaken by the stabilization manager Morgan Stanley Asia Limited, or its affiliates or any person acting on their behalf during the price stabilization period are set out as follows: (1) over-allocation of an aggregate of 12.8217 million H shares under the international offering, representing approximately 15% of the total number of offer shares available for subscription under the global offering; and (2) the overall coordinators fully exercised the over-allotment option on August 6, 2025 at HK$35.00 per H share, involving an aggregate of 5.5293 million H shares, in order to deliver some of the H shares to placees who agreed to the delayed delivery of the relevant H shares they subscribed for under the global offering. During the price stabilization period, the stabilization manager did not purchase or sell any H shares in the market for price stabilization purposes. Following the conclusion of the price stabilization period, the company will continue to comply with the public float requirements under Rule 19A.13A of the Listing Rules.